AbbVie Expands IBD Drug Pipeline Again With $250M Celsius Therapeutics Acquisition
Posted
Frank Vinluan (via MedCity News)
AbbVie has acquired Celsius Therapeutics, a startup whose lead program is in early clinical development for inflammatory bowel disease. It’s the latest in a series of AbbVie business deals that broaden the pharma company’s scope in the gastrointestinal condition.
The post AbbVie Expands IBD Drug Pipeline Again With $250M Celsius Therapeutics Acquisition appeared first on MedCity News.
